drugset / Trial / NCT01143402

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

NCT01143402

Phase 2 Completed 120 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective than selumetinib in treating melanoma of the eye.

Timeline

Start
2010-06
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 1000 mg/m2 Intravenous
Subject Selumetinib Small molecule 75 mg Oral
Subject Temozolomide Small molecule 150 mg/m2 Oral